Education
About Us
Working with TipRanks
Follow Us
IO Biotech (IOBT)
NASDAQ:IOBT
IOBT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.66 - $1.79
Previous CloseN/A
Volume57.25K
Average Volume (3M)198.32K
Market Cap
$59.82M
Enterprise Value$2.49M
Total Cash (Recent Filing)-$7.85M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.22
Next Earnings
May 19, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding65,880,910
10 Day Avg. Volume120,508
30 Day Avg. Volume198,316
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.30
Enterprise Value/Ebitda-0.03
Forecast
1Y Price Target
$9.00Price Target Upside857.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
IO Biotech News
PremiumCompany Announcements
IO Biotech Advances Phase 3 Trial and Secures Financing
PremiumCompany Announcements
IO Biotech Secures €57.5 Million EIB Loan Facility---
Bulls Say, Bears Say
Bulls Say
Analyst ConfidenceThe analyst's Buy rating and $12 price target are based on a discounted cash flow analysis, indicating confidence in the company's future potential.
Clinical TrialsThe Phase 1 study showed a median PFS of 22.5 months with IO102-IO103 + nivolumab, compared to the expected 11-12 months with checkpoint inhibitors alone.
Financial PerformanceThe company ended 2024 with $60 million in cash and equivalents, which is projected to be sufficient to fund operations into 2026.
Bears Say
Clinical RisksThe company faces risks such as safety signals in clinical programs, lower-than-expected efficacy, and greater-than-expected commercial competition.
Delisting RiskThere is a risk of delisting if the company's shares go under $1.
Operating ExpensesThe company's operating expenses are expected to increase significantly due to launch readiness for Cylembio and continuation of the Phase 3 study.
---
Ownership Overview
28.12% Insiders
0.31% Mutual Funds
21.16% Other Institutional Investors
50.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IOBT FAQ
What was IO Biotech’s price range in the past 12 months?
IO Biotech lowest stock price was $0.66 and its highest was $1.79 in the past 12 months.
What is IO Biotech’s market cap?
IO Biotech’s market cap is $59.82M.
When is IO Biotech’s upcoming earnings report date?
IO Biotech’s upcoming earnings report date is May 19, 2025 which is in 24 days.
How were IO Biotech’s earnings last quarter?
IO Biotech released its earnings results on Mar 27, 2025. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.384 by -$0.046.
Is IO Biotech overvalued?
According to Wall Street analysts IO Biotech’s price is currently Undervalued.
Does IO Biotech pay dividends?
IO Biotech does not currently pay dividends.
What is IO Biotech’s EPS estimate?
IO Biotech’s EPS estimate is -0.37.
How many shares outstanding does IO Biotech have?
IO Biotech has 65,880,910 shares outstanding.
What happened to IO Biotech’s price movement after its last earnings report?
IO Biotech reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.384. Following the earnings report the stock price went down -3.333%.
Which hedge fund is a major shareholder of IO Biotech?
Among the largest hedge funds holding IO Biotech’s share is RA Capital Management. It holds IO Biotech’s shares valued at 0.
---
IO Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (857.45% Upside)
$9.00 (857.45% Upside)
Blogger Sentiment
Bullish
IOBT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $26.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.05%
12-Months-Change
Fundamentals
Return on Equity
-106.00%
Trailing 12-Months
Asset Growth
-55.08%
Trailing 12-Months
Company Description
IO Biotech
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
---
IOBT Stock 12 Month Forecast
Average Price Target
$9.00
▲(857.45% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Avalo Therapeutics
―
Cabaletta Bio
―
Kronos Bio
―
Biomea Fusion
―
Best Analysts Covering IOBT
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-28.29%
assigned a buy rating 5 months ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -28.29% per trade.
---